Y-Biologics
Financials
Valuation Metrics
Y-Biologics's Market Cap is ₩1348B. At end of 2025 it was ₩3527B. Ranked #1005 of 2,410 in KR market (top 42%), #499 of 1,631 on KOSDAQ (top 31%), #120 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 134.78B KRW | KR#1,005/2,410 Sec#120/231 |
| Revenue | 3.17B KRW | KR#2,357/2,410 Sec#204/231 |
| Net Income | -49.95B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 50.19B KRW | KR#2,201/2,410 Sec#199/231 |
| Net Assets | 17.20B KRW | KR#2,318/2,410 Sec#218/231 |
| Employees | 60 | KR#1,959/2,410 Sec#173/231 |
| Value | ||
| P/B | 7.80x | KR#2,337/2,410 Sec#207/231 |
| P/S | 42.32x | KR#2,360/2,410 Sec#197/231 |
| FCF Yield | -5.09% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROA | -99.52% | KR#2,385/2,410 Sec#227/231 |
| Op. Margin | -415.87% | KR#2,348/2,410 Sec#201/231 |
| Revenue Growth | -46.81% | KR#2,271/2,410 Sec#203/231 |
| Financial Health | ||
| Debt Ratio | 191.84% | KR#2,069/2,410 Sec#214/231 |
| Total Debt | 16.10B KRW | KR#1,462/2,410 Sec#122/231 |
| FCF | -6.86B KRW | KR#1,581/2,410 Sec#129/231 |
| Cash | 2.51B KRW | KR#2,194/2,410 Sec#210/231 |
| Current Ratio | 23.81x | KR#17/2,410 Sec#7/231 |
| Performance | ||
| 1Y Return | -61.88% | KR#2,071/2,410 Sec#189/231 |
| 1M Return | 2.23% | KR#108/2,410 Sec#7/231 |
| From 52W High | -77.08% | KR#2,219/2,410 Sec#199/231 |
| 1Y MDD | -81.18% | KR#2,303/2,410 Sec#209/231 |
| Trading | ||
| Volume | 23,588 shares | KR#961/2,410 Sec#96/231 |
| Trading Value | 205.9M KRW | KR#829/2,410 Sec#85/231 |
| Foreign Own. | 6.70% | KR#665/2,410 Sec#58/231 |
| Per Share | ||
| EPS | -3,243 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,116 KRW | KR#2,279/2,410 Sec#207/231 |
Company Info
Y-BIOLOGICS, established in 2007 and listed on KOSDAQ in 2023, focuses on antibody drug research and development. The company leverages its antibody discovery and T-cell bispecific antibody platforms for new drug development, pursuing commercialization through technology transfer and contract research services with global pharmaceutical partners. It has also developed the Multi-AbKine platform for next-generation PD-1 new drugs, employing pH-sensitive antibody mechanism Antibody-Drug Conjugates (ADCs) to specifically target cancer cells.